Sign in

Publications

Search in 13066 publications:

RSS
Time frame
13066 Publication(s)
Jan 6, 2022
Neue Therapieverfahren und spannende Sprechstunden in der Gynäkologie (Vorsitzende)
Hülder T (2022). Neue Therapieverfahren und spannende Sprechstunden in der Gynäkologie (Vorsitzende). Presented at: Neujahrsfortbildung Frauenklinik 2022, St. Gallen
Jan 6, 2022
Neue Therapieverfahren und spannende Sprechstunden in der Gynäkologie (Vorsitzende)
Jan 6, 2022

Neujahrsfortbildung Frauenklinik 2022

Hülder Tanja

more
Jan 6, 2022
Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol.
Gaastra B, Alexander S, Bakker M, Bhagat H, Bijlenga P, Blackburn S, Collins M, Doré S, Griessenauer C, Hendrix P, Hong E, Hostettler I, Houlden H, IIhara K, Jeon J, Kim B, Kumar M, Morel S, Nyquist P, Ren D, Ruigrok Y, Werring D, Galea I, Bulters D, Tapper W. Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol. Transl Stroke Res 2022; 13:565-576.
Jan 6, 2022
Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol.
Jan 6, 2022

Transl Stroke Res 2022; 13:565-576

Gaastra Ben, Alexander Sheila, Bakker Mark K, Bhagat Hemant, Bijlenga Philippe, Blackburn Spiros, Collins Malie K, Doré Sylvain, Griessenauer Christoph J, Hendrix Philipp, Hong Eun Pyo, Hostettler Isabel C, Houlden Henry, IIhara Koji, Jeon Jin Pyeong, Kim Bong Jun, Kumar Munish, Morel Sandrine, Nyquist Paul, Ren Dianxu, Ruigrok Ynte M, Werring David, Galea Ian, Bulters Diederik, Tapper Will

more
Jan 4, 2022
Association of the COVID-19 outbreak with acute stroke care in Switzerland.
De Marchis G, Wright P, Michel P, Strambo D, Carrera E, Dirren E, Luft A, Wegener S, Cereda C, Kägi G, Vehoff J, Gensicke H, Lyrer P, Nedeltchev K, Khales T, Bolognese M, Salmen S, Sturzenegger R, Bonvin C, Berger C, Schelosky L, Mono M, Rodic B, von Reding A, Schwegler G, Tarnutzer A, Medlin F, Humm A, Peters N, Beyeler M, Kriemler L, Bervini D, Fandino J, Hemkens L, Mordasini P, Arnold M, Fischer U, Bonati L, Swiss Stroke Registry Investigators. Association of the COVID-19 outbreak with acute stroke care in Switzerland. Eur J Neurol 2022; 29:724-731.
Jan 4, 2022
Association of the COVID-19 outbreak with acute stroke care in Switzerland.
Jan 4, 2022

Eur J Neurol 2022; 29:724-731

De Marchis Gian Marco, Wright Patrick R, Michel Patrik, Strambo Davide, Carrera Emmanuel, Dirren Elisabeth, Luft Andreas R, Wegener Susanne, Cereda Carlo W, Kägi Georg, Vehoff Jochen, Gensicke Henrik, Lyrer Philippe A, Nedeltchev Krassen, Khales Timo, Bolognese Manuel, Salmen Stephan, Sturzenegger Rolf, Bonvin Christophe, Berger Christian, Schelosky Ludwig D., Mono Marie-Luise, Rodic Biljana, von Reding Andrea, Schwegler Guido, Tarnutzer Alexander A., Medlin Friedrich, Humm Andrea M, Peters Nils, Beyeler Morin, Kriemler Lilian, Bervini David, Fandino Javier, Hemkens Lars G, Mordasini Pasquale, Arnold Marcel, Fischer Urs, Bonati Leo H, Swiss Stroke Registry Investigators

more
Jan 3, 2022
Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
Beck M, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti D, Reuter C, Gomez S, Khanfir K, Aebersold D, Ghadjar P, Schär C, Hayoz S, Papachristofilou A, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen D, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller A, Putora P, Pra A. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. Int J Radiat Oncol Biol Phys 2022; 113:80-91.
Jan 3, 2022
Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
Jan 3, 2022

Int J Radiat Oncol Biol Phys 2022; 113:80-91

Beck Marcus, Li Qiyu, Sumila Marcin, Zaugg Kathrin, Guckenberger Matthias, Ost Piet, Bosetti Davide G, Reuter Christiane, Gomez Silvia, Khanfir Kaouthar, Aebersold Daniel M, Ghadjar Pirus, Schär Corinne, Hayoz Stefanie, Papachristofilou Alexandros, Sassowsky Manfred, Schär Sämi, Mathier Etienne, Halter Matthias, Zwahlen Daniel R, Hölscher Tobias, Arnold Winfried, Polat Bülent, Hildebrandt Guido, Müller Arndt-Christian, Putora Paul Martin, Pra Alan Dal

more
Jan 3, 2022
The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).
König R, Albrich W, Kahlert C, Bahr L, Löber U, Vernazza P, Scheibenbogen C, Forslund S. The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). Front Immunol 2022; 12:628741.
Jan 3, 2022
The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).
Jan 3, 2022

Front Immunol 2022; 12:628741

König Rahel S, Albrich Werner, Kahlert Christian, Bahr Lina Samira, Löber Ulrike, Vernazza Pietro, Scheibenbogen Carmen, Forslund Sofia K

more
Jan 1, 2022
[Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics].
Popp J, Georgescu D, Bürge M, Mundwiler-Pachlatko E, Bernasconi L, Felbecker A. [Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]. Praxis (Bern 1994) 2022; 111:738-744.
Jan 1, 2022
[Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics].
Jan 1, 2022

Praxis (Bern 1994) 2022; 111:738-744

Popp Julius, Georgescu Dan, Bürge Markus, Mundwiler-Pachlatko Esther, Bernasconi Luca, Felbecker Ansgar

more
Jan 1, 2022
Interleukin-6 Is an Early Plasma Marker of Severe Postoperative Complications in Thoracic Surgery: Exploratory Results From a Substudy of a Randomized Controlled Multicenter Trial.
Neff T, Braun J, Rana D, Puhan M, Filipovic M, Seeberger M, Stuber F, Neff S, Beck-Schimmer B, Schläpfer M. Interleukin-6 Is an Early Plasma Marker of Severe Postoperative Complications in Thoracic Surgery: Exploratory Results From a Substudy of a Randomized Controlled Multicenter Trial. Anesth Analg 2022; 134:123-132.
Jan 1, 2022
Interleukin-6 Is an Early Plasma Marker of Severe Postoperative Complications in Thoracic Surgery: Exploratory Results From a Substudy of a Randomized Controlled Multicenter Trial.
Jan 1, 2022

Anesth Analg 2022; 134:123-132

Neff Thomas A, Braun Julia, Rana Dhanu, Puhan Milo, Filipovic Miodrag, Seeberger Manfred, Stuber Frank, Neff Simona B, Beck-Schimmer Beatrice, Schläpfer Martin

more
Jan 1, 2022
Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?
Putora P, De Ruysscher D. Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?. J Thorac Oncol 2022; 17:487-488.
Jan 1, 2022
Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?
Jan 1, 2022

J Thorac Oncol 2022; 17:487-488

Putora Paul Martin, De Ruysscher Dirk

more
Jan 1, 2022
EJVES - a Look Ahead
Dick F, Björck M. EJVES - a Look Ahead. Eur J Vasc Endovasc Surg 2022; 63:1-2.
Jan 1, 2022
EJVES - a Look Ahead
Jan 1, 2022

Eur J Vasc Endovasc Surg 2022; 63:1-2

Dick Florian, Björck Martin

more
Jan 1, 2022
Schwere Hypophosphatämie nach Eiseninfusion
Wimmersberger D, Mani L, Zanchin C, Kuhn C, Messi M, Günther G, Wertli M, Martin Y. Schwere Hypophosphatämie nach Eiseninfusion. Swiss Medical Forum 2022
Jan 1, 2022
Schwere Hypophosphatämie nach Eiseninfusion
Jan 1, 2022

Swiss Medical Forum 2022

Wimmersberger David, Mani Laila-Yasmin, Zanchin Christian, Kuhn Christian, Messi Mia, Günther Gunar, Wertli Maria, Martin Yonas

more
Jan 1, 2022
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Schmiedeberg K, Abela I, Pikor N, Vuilleumier N, Schwarzmueller M, Epp S, Pagano S, Grabherr S, Patterson A, Nussberger M, Trkola A, Ludewig B, von Kempis J, Rubbert-Roth A. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open 2022; 8
Jan 1, 2022
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Jan 1, 2022

RMD Open 2022; 8

Schmiedeberg Kristin, Abela Irene A, Pikor Natalia, Vuilleumier Nicolas, Schwarzmueller Magdalena, Epp Selina, Pagano Sabrina, Grabherr Sarah, Patterson Angelica Brooke, Nussberger Madalina, Trkola Alexandra, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea

more
Jan 1, 2022
A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2.
Albrich W, Ghosh T, Ahearn-Ford S, Mikaeloff F, Lunjani N, Forde B, Suh N, Kleger G, Pietsch U, Frischknecht M, Garzoni C, Forlenza R, Horgan M, Sadlier C, Negro T, Pugin J, Wozniak H, Cerny A, Neogi U, O'Toole P, O'Mahony L. A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. Gut Microbes 2022; 14:2073131.
Jan 1, 2022
A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2.
Jan 1, 2022

Gut Microbes 2022; 14:2073131

Albrich Werner, Ghosh Tarini Shankar, Ahearn-Ford Sinead, Mikaeloff Flora, Lunjani Nonhlanhla, Forde Brian, Suh Noémie, Kleger Gian-Reto, Pietsch Urs, Frischknecht Manuel, Garzoni Christian, Forlenza Rossella, Horgan Mary, Sadlier Corinna, Negro Tommaso Rochat, Pugin Jérôme, Wozniak Hannah, Cerny Andreas, Neogi Ujjwal, O'Toole Paul W, O'Mahony Liam

more
Jan 1, 2022
[Therapy of Heart Failure with Reduced Ejection Fraction: What's New in the 2021 Guidelines?].
Maeder M, Rickli H, Brenner R, Scheler E, Buser M. [Therapy of Heart Failure with Reduced Ejection Fraction: What's New in the 2021 Guidelines?]. Praxis (Bern 1994) 2022; 111:445-456.
Jan 1, 2022
[Therapy of Heart Failure with Reduced Ejection Fraction: What's New in the 2021 Guidelines?].
Jan 1, 2022

Praxis (Bern 1994) 2022; 111:445-456

Maeder Micha, Rickli Hans, Brenner Roman, Scheler Eva, Buser Marc

more
Jan 1, 2022
[Non-antibiotic Prophylaxis of Infections].
Seneghini M, Albrich W. [Non-antibiotic Prophylaxis of Infections]. Praxis (Bern 1994) 2022; 111:463-468.
Jan 1, 2022
[Non-antibiotic Prophylaxis of Infections].
Jan 1, 2022

Praxis (Bern 1994) 2022; 111:463-468

Seneghini Marco, Albrich Werner

more
Jan 1, 2022
[How Myelodysplastic Syndrome is Diagnosed].
Silzle T. [How Myelodysplastic Syndrome is Diagnosed]. Ther Umsch 2022; 78:77-85.
Jan 1, 2022
[How Myelodysplastic Syndrome is Diagnosed].
Jan 1, 2022

Ther Umsch 2022; 78:77-85

Silzle Tobias

more
Jan 1, 2022
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban J, Kägi G, Raw J, Stefani A, Warnecke T, Jost W, SYNAPSES Study Investigators Group. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. J Parkinsons Dis 2022; 12:473.
Jan 1, 2022
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Jan 1, 2022

J Parkinsons Dis 2022; 12:473

Abbruzzese Giovanni, Kulisevsky Jaime, Bergmans Bruno, Gomez-Esteban Juan C, Kägi Georg, Raw Jason, Stefani Alessandro, Warnecke Tobias, Jost Wolfgang H, SYNAPSES Study Investigators Group

more
Jan 1, 2022
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
van Rees D, Saura C, Di Cosimo S, Huober J, Roylance R, Kim S, Kuijpers T, van Bruggen R, K van den Berg T, Guillaume S, Izquierdo M, El-Abed S, Bouti P, Klein B, Verkuijlen P, van Houdt M, Schornagel K, Tool A, Venet D, Sotiriou C, Matlung H. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. J Immunother Cancer 2022; 10
Jan 1, 2022
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
Jan 1, 2022

J Immunother Cancer 2022; 10

van Rees Dieke J, Saura Cristina, Di Cosimo Serena, Huober Jens, Roylance Rebecca, Kim Sung-Bae, Kuijpers Taco W, van Bruggen Robin, K van den Berg Timo, Guillaume Sébastien, Izquierdo Miguel, El-Abed Sarra, Bouti Panagiota, Klein Bart, Verkuijlen Paul J H, van Houdt Michel, Schornagel Karin, Tool Anton T J, Venet David, Sotiriou Christos, Matlung Hanke L

more
Jan 1, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
Jan 1, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Jan 1, 2022

JAMA Oncol 2022; 8:1010-1018

Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B

more
Jan 1, 2022
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Mueller R, Schulze-Koops H, Furst D, Cohen S, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol 2022; 41:1045-1055.
Jan 1, 2022
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Jan 1, 2022

Clin Rheumatol 2022; 41:1045-1055

Mueller Ruediger B, Schulze-Koops Hendrik, Furst Daniel E, Cohen Stanley B, Kwok Kenneth, Wang Lisy, Killeen Tim, von Kempis Johannes

more
Dec 30, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Burmester G, Liu J, Mccaskill R, Lertratanakul A, Lippe R, Lesser E, Rubbert-Roth A, Salvarani C, Azevedo V, Goupille P, Nash P, Blanco R, Winthrop K, Ruderman E. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatol Ther 2021
Dec 30, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Dec 30, 2021

Rheumatol Ther 2021

Burmester Gerd R, Liu John, Mccaskill Reva M, Lertratanakul Apinya, Lippe Ralph, Lesser Elizabeth, Rubbert-Roth Andrea, Salvarani Carlo, Azevedo Valderilio F, Goupille Philippe, Nash Peter, Blanco Ricardo, Winthrop Kevin, Ruderman Eric M

more

We use cookies and tracking technologies according to our privacy policy to provide you with the best possible web experience. To the privacy policy